The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C
- PMID: 11719451
The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C
Abstract
Activation of the phosphatidylinositol 3'-kinase (PI3K)/Akt survival pathway protects against apoptotic stress stimuli. Therefore, compounds that down-regulate this pathway are of clinical interest for single and combined anticancer treatment modalities. Here we demonstrate that the cytotoxic effect of the protein kinase C (PKC)-inhibitor N-benzoylated staurosporine (PKC412) is mediated via the PI3K/Akt pathway. Dose-dependent down-regulation of the proliferative activity, activation of the apoptotic machinery, and cell killing by PKC412 (0-1 microM) in Rat1a-fibroblasts and H-ras-oncogene-transformed fibroblasts correlated with a decrease of Akt phosphorylation and a reduced phosphorylation of the endogenous Akt-substrate GSK3-alpha. Expression of the dominant-active myristoylated form of Akt abrogated this cytotoxic effect of PKC412. Experiments with Apaf-1-deficient cells revealed that PKC412-induced cytotoxicity depends on an intact apoptosome but that the decrease of Akt phosphorylation is not attributable to apoptosis execution. Comparative experiments indicate that PKC412 and the parent-compound staurosporine down-regulate this survival pathway upstream or at the level of Akt but by a different mechanism than the PI3K-inhibitor LY294002. Furthermore, inhibition of this pathway by PKC412 is relevant for sensitization to ionizing radiation. These results demonstrate the specific role of this signaling pathway for the PKC412-mediated down-regulation of an apoptotic threshold and its cytotoxicity.
Similar articles
-
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.Leukemia. 2003 Sep;17(9):1794-805. doi: 10.1038/sj.leu.2403044. Leukemia. 2003. PMID: 12970779
-
Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.Clin Cancer Res. 2005 Apr 15;11(8):3102-8. doi: 10.1158/1078-0432.CCR-04-1857. Clin Cancer Res. 2005. PMID: 15837766
-
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.Cancer Res. 2003 Apr 15;63(8):1822-33. Cancer Res. 2003. PMID: 12702569
-
Phosphatidylinositide 3-kinase/AKT in radiation responses.Histol Histopathol. 2004 Jul;19(3):915-23. doi: 10.14670/HH-19.915. Histol Histopathol. 2004. PMID: 15168354 Review.
-
The Akt pathway: molecular targets for anti-cancer drug development.Curr Cancer Drug Targets. 2004 May;4(3):235-56. doi: 10.2174/1568009043333032. Curr Cancer Drug Targets. 2004. PMID: 15134532 Review.
Cited by
-
Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054. Oncotarget. 2016. PMID: 27527856 Free PMC article.
-
Effects of the PKC inhibitor PD 406976 on cell cycle progression, proliferation, PKC isozymes and apoptosis in glioma and SVG-transformed glial cells.Cell Prolif. 2005 Apr;38(2):87-106. doi: 10.1111/j.1365-2184.2005.00333.x. Cell Prolif. 2005. PMID: 15842253 Free PMC article.
-
Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.Transl Oncol. 2008 Dec;1(4):195-201. doi: 10.1593/tlo.08151. Transl Oncol. 2008. PMID: 19043530 Free PMC article.
-
Targeting Protein Kinase C Downstream of Growth Factor and Adhesion Signalling.Cancers (Basel). 2015 Jul 15;7(3):1271-91. doi: 10.3390/cancers7030836. Cancers (Basel). 2015. PMID: 26184315 Free PMC article. Review.
-
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.J Biol Chem. 2015 Jul 24;290(30):18480-94. doi: 10.1074/jbc.M114.633693. Epub 2015 Jun 17. J Biol Chem. 2015. PMID: 26085088 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous